New drug combo aims to control advanced skin cancer
NCT ID NCT03149029
Summary
This study is testing whether a short course of two targeted cancer drugs (trametinib and dabrafenib), given alongside an immunotherapy drug (pembrolizumab), works better than expected for people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps control the cancer for a longer period. All 16 participants have advanced melanoma with a specific genetic change (BRAF mutation).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.